Tags

Type your tag names separated by a space and hit enter

Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results.
Bone Marrow Transplant. 1993; 12 Suppl 3:S7-10.BM

Abstract

Acute and chronic graft-versus-host disease (GVHD) are responsible for a significant fraction of the morbidity and mortality of allogeneic bone marrow transplantation. Attempts to reduce the incidence of GVHD by exhaustive T cell depletion of donor marrow have frequently been associated with an increase in graft failure and disease relapse. For the past 10 years, we have evaluated the use of a monoclonal antibody (T12) that selectively targets the CD6 determinant on mature T cells. 171 patients with hematologic malignancies have received donor marrow depleted of mature T cells with anti-CD6 and rabbit complement. Initial engraftment in recipients of HLA-matched marrow has been > 98% with 96% of patients showing stable hematologic reconstitution. The incidence of acute GVHD in this population was only 15%. Chronic GVHD has developed in 5% of patients. Overall, transplant-related mortality was 17%. Examination of peripheral blood lymphocyte reconstitution in the early post-BMT period has been helpful in predicting which patients will ultimately go on to develop GVHD. Treatment of recipients of CD6 depleted marrow with low doses of interleukin-2 post-BMT can expand the number of circulating NK cells and may be associated with a decrease in disease relapse rate.

Authors+Show Affiliations

Dana-Farber Cancer Institute, Boston, MA 02115.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8124262

Citation

Soiffer, R J., and J Ritz. "Selective T Cell Depletion of Donor Allogeneic Marrow With anti-CD6 Monoclonal Antibody: Rationale and Results." Bone Marrow Transplantation, vol. 12 Suppl 3, 1993, pp. S7-10.
Soiffer RJ, Ritz J. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. Bone Marrow Transplant. 1993;12 Suppl 3:S7-10.
Soiffer, R. J., & Ritz, J. (1993). Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. Bone Marrow Transplantation, 12 Suppl 3, S7-10.
Soiffer RJ, Ritz J. Selective T Cell Depletion of Donor Allogeneic Marrow With anti-CD6 Monoclonal Antibody: Rationale and Results. Bone Marrow Transplant. 1993;12 Suppl 3:S7-10. PubMed PMID: 8124262.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. AU - Soiffer,R J, AU - Ritz,J, PY - 1993/1/1/pubmed PY - 1993/1/1/medline PY - 1993/1/1/entrez SP - S7 EP - 10 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 12 Suppl 3 N2 - Acute and chronic graft-versus-host disease (GVHD) are responsible for a significant fraction of the morbidity and mortality of allogeneic bone marrow transplantation. Attempts to reduce the incidence of GVHD by exhaustive T cell depletion of donor marrow have frequently been associated with an increase in graft failure and disease relapse. For the past 10 years, we have evaluated the use of a monoclonal antibody (T12) that selectively targets the CD6 determinant on mature T cells. 171 patients with hematologic malignancies have received donor marrow depleted of mature T cells with anti-CD6 and rabbit complement. Initial engraftment in recipients of HLA-matched marrow has been > 98% with 96% of patients showing stable hematologic reconstitution. The incidence of acute GVHD in this population was only 15%. Chronic GVHD has developed in 5% of patients. Overall, transplant-related mortality was 17%. Examination of peripheral blood lymphocyte reconstitution in the early post-BMT period has been helpful in predicting which patients will ultimately go on to develop GVHD. Treatment of recipients of CD6 depleted marrow with low doses of interleukin-2 post-BMT can expand the number of circulating NK cells and may be associated with a decrease in disease relapse rate. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/8124262/Selective_T_cell_depletion_of_donor_allogeneic_marrow_with_anti_CD6_monoclonal_antibody:_rationale_and_results_ L2 - https://medlineplus.gov/bonemarrowtransplantation.html DB - PRIME DP - Unbound Medicine ER -